We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cresset BioMolecular Discovery Launches FieldStere

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cresset BioMolecular Discovery Launches FieldStere"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cresset BioMolecular Discovery Ltd announces the launch of FieldStere, a new software product that enables medicinal chemists to enrich their shortlist of drug candidates with structurally diverse compounds that share the same desired biological activity (bioisosteres).

FieldStere allows the fine-tuning of the resulting bioisosteres to enhance potency and specificity whilst removing undesirable ADME and physical properties.

The new FieldStere product builds on Cresset’s proprietary Field technology, which describes chemical structures in terms of the surface properties of the whole molecule. These determine, much more accurately than existing tools, how a compound will interact with other molecules.

FieldStere was developed at the request of Cresset’s clients. “Our clients recognized the potential of our Field technology in a range of areas such as lead optimization, candidate switching, compound evaluation and investigation of new patent opportunities around existing therapeutics,” said Bea Leigh, CEO of Cresset. “In pre-launch testing with existing biotech and pharmaceutical customers, FieldStere performed outstandingly well and received very positive feedback. Users reported that the product consistently identified both known bioisosteres and non-obvious, structurally diverse compounds.”

These non-obvious compounds increase the medicinal chemistry repertoire and can represent novel product opportunities unprotected by existing patents. As a result, FieldStere has application in the development of patent strategy for the protection of new molecular entities, identifying follow-on compounds as marketed products come off patent and lead optimization of new drugs.

“In today’s climate, FieldStere is a promising new tool that allows me to rapidly identify novel chemistry to solve biological problems, and offers a potential route to open up new therapeutic opportunities” commented Dr. Caroline Low, Head of Molecular Modeling and CADD at the Drug Discovery Centre, Imperial College, London.

FieldStere will be sold through Cresset’s sales operations and offered as part of a leveraged service offering to companies that need to access specialist chemistry services.